In an observational cohort study of RA patients with hba1c measurements before and after initiation of tocilizumab compared to a tumor necrosis factor inhibitor, a larger reduction in hba1c was observed in the tocilizumab group43. The gene discussed is TNF; the disease is rheumatoid arthritis.